Stockholders approve amendment increasing share reserve by 4.05M shares

Kura Oncology, Inc.

At May 31 annual meeting, stockholders approved Amended 2014 Plan increasing authorized shares by 4,050,000.
Diane Parks and Mary T. Szela elected as Class III directors until 2026 annual meeting.
Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec 31, 2023.
Advisory vote on executive compensation approved with ~52M for vs ~0.88M against.
Amended 2014 Plan approved with ~46.8M for, ~5.9M against, ~1.4M abstain.

item 5.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Kura Oncology, Inc. shareholders approved Election of Class III Directors at the 2023-05-31 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-31

Exact text from the filing

Name of Director Elected For Withheld Broker Non-Votes Diane Parks 39,370,803 14,742,373 1,860,281 Mary T. Szela 53,945,761 167,415 1,860,281

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Kura Oncology, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2023-05-31 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-31

Exact text from the filing

For Against Abstain Broker Non-Votes 55,916,556 34,565 22,336 —

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Kura Oncology, Inc. shareholders approved Approval of Amended 2014 Plan at the 2023-05-31 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-05-31

Exact text from the filing

For Against Abstain Broker Non-Votes 46,803,922 5,914,387 1,394,867 1,860,281

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Kura Oncology, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-05-31 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-05-31

Exact text from the filing

For Against Abstain Broker Non-Votes 51,834,962 879,497 1,398,717 1,860,281

View on SEC.gov

352 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-026086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.